Bexarotene: A Novel Drug Delivery System for Cutaneous T-cell Lymphoma (CTCL)
DOI:
https://doi.org/10.61841/962c2q81Keywords:
Bexarotene, skin manifestations, “cutaneous T-cell lymphoma (CTCL)”, non-Hodgkin lymphomas (NHLs), extracutaneous disease, polymeric-zeinnanomicelles, nanocarriers, nanomicellesAbstract
Bexarotene is an analogue which is used as skin manifestations therapy of the “cutaneous T-cell lymphoma (CTCL)”. Its therapy is highly associated with the enhancement in the concentration of serum enzyme and reduces the chances of acute liver iunjury. “Cutaneous T-cell lymphoma (CTCL)” is a member of the family “non-Hodgkin lymphomas” (which are related to the B-cells), and is caused by the mutation of T-cells. They are predominantly found in the skin and are a heterogeneous and relatively rare family of extranodal non-Hodgkin's lymphomas (NHLs). Some patients have dermal spots, plaques, tumors and erythroderma more rarely. The most important prognostic factors in CTCL patients are the type of skin lesions and the surface extent of skin infection and extracutaneous disease. Early-stage patients can only be treated effectively by skin-directed therapies. In this paper, we have talked about the development and characterization of Polymeric-zeinnanomicelles base formulation of Bexarotene for the treatment of “cutaneous T-cell lymphoma (CTCL)”. The Pegylated-zeinnanomicelles were evaluated as nanocarriers to improve the efficacy, reduced toxicity in vivo, protection of encapsulated agent against degradation and enhanced water solubility of hydrophobic bexarotene as a novel delivery system for “cutaneous Tcell lymphoma (CTCL)”. For this, the formulation of nanomicelle drug delivery comprising the Pegylatedzeinnanomicelles encapsulates the bexarotene in two different ratios and then the results were evaluated accordingly.
Downloads
References
[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA. Cancer J. Clin., 2015.
[2] J. F. A. Murphy, “The global burden of disease,” Ir. Med. J., 2013.
[3] P. C. Registry, “Global Cancer Observatory,” Malaysia Cancer Stat., 2019.
[4] B. W. Stewart and C. P. Wild, “World cancer report 2014,” World Heal. Organ., 2014.
[5] F. R. Schram and P. K. L. Ng, “What is cancer?,” J. Crustac. Biol., 2012.
[6] Z. Burningham, M. Hashibe, L. Spector, and J. D. Schiffman, “The Epidemiology of Sarcoma,” Clin.
Sarcoma Res., 2012.
[7] S. K. Tantravahi and T. Kovacsovics, “Myeloma,” in Metastatic Bone Disease: An Integrated Approach to
Patient Care, 2015
[8] T. Lightfoot, A. Smith, and E. Roman, “Leukemia,” in International Encyclopedia of Public Health, 2016.
[9] S. Cherrier-De Wilde, “Lymphoma,” in Side Effects of Medical Cancer Therapy: Prevention and
[10] S. H. Swerdlowet al., “The 2016 revision of the World Health Organization classification of lymphoid
neoplasms,” Blood. 2016.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
